scholarly journals The Effect of Vitamin D Supplementation on Blood Lipids in Patients with Polycystic Ovary Syndrome: A Meta-Analysis of Randomized Controlled Trials

2021 ◽  
Vol 2021 ◽  
pp. 1-9
Author(s):  
Hong Gao ◽  
YanTao Li ◽  
WenNan Yan ◽  
Fei Gao
Keyword(s):  
Vitamin D ◽  
Polycystic Ovary Syndrome ◽  
Cholesterol Level ◽  
Blood Lipids ◽  
Polycystic Ovary ◽  
Meta Analysis ◽  
Density Lipoprotein ◽  
Vitamin D Supplementation ◽  
Lipoprotein Cholesterol ◽  
Ovary Syndrome

Purpose. Studies have found that vitamin D supplementation may improve blood lipids in patients with polycystic ovary syndrome, but the results are controversial, so this study will further analyze the effect of vitamin D supplementation on blood lipids in patients with polycystic ovary syndrome. Methods. PubMed, Embase, Cochrane Library, CNKI, and Wanfang databases were searched up to May 2020, to identify randomized controlled trials of the effect of vitamin D supplementation on blood lipids in patients with polycystic ovary syndrome. The Cochrane risk of bias tool was applied to assess the risk of bias, and RevMan5.3 software was used for statistical analysis. Results. Ten studies were included in this study, including 543 subjects. The results of the meta-analysis showed that, compared with placebo, vitamin D supplementation can significantly reduce total cholesterol level (WMD = –11.32, 95% CI = [–14.51, –8.41], P < 0.00001 ), low-density lipoprotein cholesterol level (WMD = –4.83, 95% CI = [–7.52, –2.14], P = 0.0004 ), and triglyceride level (WMD = –8.23, 95% CI = [–13.08, –3.38], P = 0.0009 , but the effect on high-density lipoprotein cholesterol level is not statistically significant (WMD = –0.32, 95%CI = [–1.24, 0.60], P = 0.50 ). Conclusion. Vitamin D supplementation can significantly reduce total cholesterol, low-density lipoprotein cholesterol, and triglycerides in patients with polycystic ovary syndrome. However, it has no significant effect on high-density lipoprotein cholesterol.

scholarly journals The Effects of Salvia miltiorrhiza on Reproduction and Metabolism in Women with Polycystic Ovary Syndrome: A Systematic Review and Meta-Analysis

2021 ◽  
Vol 2021 ◽  
pp. 1-12
Author(s):  
Wenjuan Shen ◽  
Bao Jin ◽  
Yaguang Han ◽  
Hongwei Wang ◽  
Huan Jiang ◽  
...  
Keyword(s):  
Systematic Review ◽  
Polycystic Ovary Syndrome ◽  
Polycystic Ovary ◽  
Salvia Miltiorrhiza ◽  
Meta Analysis ◽  
Density Lipoprotein ◽  
Lipoprotein Cholesterol ◽  
Cochrane Library ◽  
Ovary Syndrome ◽  
Significant Difference

Objective. Polycystic ovary syndrome (PCOS) is the most common endocrine disorder in women of reproductive age. As a traditional medicine, Salvia miltiorrhiza (S. miltiorrhiza) has been widely used in the treatment of many gynecological diseases, but the efficacy of S. miltiorrhiza in women with PCOS has not been assessed. The purpose of this systematic review and meta-analysis was to evaluate the effectiveness and safety of S. miltiorrhiza in women with PCOS. Methods. We conducted searches in PubMed, Embase, the Cochrane Library, the China National Knowledge Infrastructure, the Wanfang Database, the Chinese Scientific Journal Database, and the Chinese BioMedical database from inception to December 23, 2020, to identify studies that met the inclusion criteria. The quality of the evidence was estimated using the Cochrane Reviewer Handbook 5.0.0, and the meta-analysis was performed using RevMan 5.3.5 software. Results. Six randomized controlled trials (RCTs) involving 390 patients with PCOS were included. The studies suggested that S. miltiorrhiza extract combined with letrozole (LET) was more effective in improving pregnancy rate (RR: 2.60, 95% CI: 1.06 to 6.39, P = 0.04 ) compared to LET alone. S. miltiorrhiza extract was associated with decreased fasting blood glucose (MD: –0.25, 95% CI: –0.37 to –0.13, P < 0.0001 ), fasting insulin (MD: –1.16, 95% CI: –1.74 to –0.58, P < 0.0001 ), total cholesterol (TC) (MD: –0.58, 95% CI: –0.72 to –0.43, P < 0.00001 ), and triglycerides (TG) (MD: –0.31, 95% CI: –0.35 to –0.26, P < 0.00001 ) compared with placebo, but not with improvements in body mass index or waist-to-hip ratio (MD: –1.41, 95% CI: –4.81 to 2.00, P = 0.42 ; MD: –0.02, 95% CI: –0.05 to 0.01, P = 0.16 , respectively). There was a significant difference between S. miltiorrhiza extract combined with cyproterone acetate (CPA) and CPA alone in terms of decreasing TC (MD: –0.77, 95% CI: –0.89 to –0.65, P < 0.00001 ), TG (MD: –0.43, 95% CI: –0.65 to –0.20, P < 0.0001 ), and low-density lipoprotein cholesterol (MD: –0.49, 95% CI: –0.66 to –0.33, P < 0.00001 ) and increasing high-density lipoprotein cholesterol (MD: 0.30, 95% CI: 0.20, 0.40, P < 0.00001 ). In addition, S. miltiorrhiza extract also decreased testosterone, follicle-stimulating hormone, and luteinizing hormone. The studies did not mention any adverse events with S. miltiorrhiza extract. Conclusion. The current studies indicate that S. miltiorrhiza has beneficial effects on reproduction and glucose and lipid metabolism in patients with PCOS, and it is generally safe for clinical application. However, more prospective RCTs with large samples, multiple centers, and longer intervention duration are needed in the future to obtain more reliable conclusions.

The role of vitamin D in metabolic and reproductive disturbances of polycystic ovary syndrome: A narrative mini-review

2020 ◽  
pp. 1-8
Author(s):  
Daniela Menichini ◽  
Gianpiero Forte ◽  
Beatrice Orrù ◽  
Giuseppe Gullo ◽  
Vittorio Unfer ◽  
...  
Keyword(s):  
Vitamin D ◽  
Polycystic Ovary Syndrome ◽  
Embryo Quality ◽  
Polycystic Ovary ◽  
Vitamin D Supplementation ◽  
Endometrial Receptivity ◽  
Metabolic Disturbances ◽  
Ovary Syndrome ◽  
Beneficial Role

Abstract. Vitamin D is a secosteroid hormone that plays a pivotal role in several metabolic and reproductive pathways in humans. Increasing evidence supports the role of vitamin D deficiency in metabolic disturbances and infertility in women with polycystic ovary syndrome (PCOS). Indeed, supplementation with vitamin D seems to have a beneficial role on insulin resistance and endometrial receptivity. On the other hand, exceedingly high levels of vitamin D appear to play a detrimental role on oocytes development and embryo quality. In the current review, we summarize the available evidence about the topic, aiming to suggest the best supplementation strategy in women with PCOS or, more generally, in those with metabolic disturbances and infertility. Based on the retrieved data, vitamin D seems to have a beneficial role on IR, insulin sensitivity and endometrial receptivity, but high levels and incorrect timing of administration seem to have a detrimental role on oocytes development and embryo quality. Therefore, we encourage a low dose supplementation (400–800 IU/day) particularly in vitamin D deficient women that present metabolic disturbances like PCOS. As far as the reproductive health, we advise vitamin D supplementation in selected populations, only during specific moments of the ovarian cycle, to support the luteal phase. However, ambiguities about dosage and timing of the supplementation still emerge from the clinical studies published to date and further studies are required.

Assessment of Serum Irisin in Overweight And Obese Patient with Polycystic Ovary Syndrome

2020 ◽  
Vol 23 (2) ◽  
pp. 25-34
Author(s):  
Sipel Younis Mustafa ◽  
Shereen. A. Ibrahim
Keyword(s):  
Polycystic Ovary Syndrome ◽  
Obese Patient ◽  
Study Design ◽  
Polycystic Ovary ◽  
Density Lipoprotein ◽  
Lipoprotein Cholesterol ◽  
Control Group ◽  
Ovary Syndrome ◽  
Serum Lh ◽  
Median Serum

Background and Objective: Polycystic ovary syndrome (PCOS) is the most common endocrine disorder affecting 10–15 % of women in reproductive age. The objective was to evaluate the effect of irisin in the etiology of obese patient with PCOS. Study Design and Methods: The study design its a case control study. This study involved fifty obese ladies (50) with confirmed diagnosis of PCOS. The second group served as control group and included forty apparently normal (non-polycystic ovary) obese ladies (40). The following main parameters were measured: Fasting serum levels of total Cholesterol, triglyceride, high density lipoprotein-cholesterol, low density lipoprotein– cholesterol, glycohaemoglobin (HbA1c%), Insulin , Testosterone, FSH, serum LH and Irisin. Results: The median serum Irisin was significantly higher among PCOS cases (119.1 ng/ml) compared to healthy controls (74.7 ng/ml). The median serum FSH was significantly higher among PCOS cases (6.52 ng/ml ) compared to controls (4.72 ng/ml). Serum LH was obviously higher among PCOS cases (6.88 ng/ml) compared to controls (6.08 ng/ml). The mean pulse rate, blood WBC count and serum VLDL were significantly higher (71.6/min, 8.3 mg/dl and 22.5 mg/dl respectively) in cases with PCOS compared to controls (67.5/min, 7.2 mg/dl and 18.5 mg/dl respectively). Conversely, the serum HDL was significantly lower among PCOS cases (43.8 mg/dl) compared to controls (48.4 mg/dl), serum testosterone showed statistically non-significant differences. Conclusion: Data of the present study showed that serum Irisin was significantly higher among PCOS cases. These findings suggest important role of irisin as a biomarker for PCOS and an important factor in the development of PCOS.

Sign in / Sign up

Export Citation Format

Share Document